BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Masitinib: Phase IIb/III started

AB Science began a double-blind, placebo-controlled, international Phase IIb/III trial to compare 3 and 6 mg/kg/day masitinib vs. methotrexate in about 450 patients with...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >